Health TidingsInsilico’s AI-Designed ISM6331 Shows Tumor Shrinkage in Mesothelioma Insilico’s AI-Designed ISM6331 Shows Tumor Shrinkage in Mesothelioma Read Post »
Health TidingsGSK’s Ris-Rez Cuts Progression Risk by 67% in Osteosarcoma Trial GSK’s Ris-Rez Cuts Progression Risk by 67% in Osteosarcoma Trial Read Post »
Clinical TrialsHenlius Reports Longer Overall Survival With Serplulimab in ES-SCLC Henlius Reports Longer Overall Survival With Serplulimab in ES-SCLC Read Post »
Clinical TrialsMerck KGaA Reports Durable Tumor Control With Pimicotinib at Two Years Merck KGaA Reports Durable Tumor Control With Pimicotinib at Two Years Read Post »
New Drug ApprovalAstraZeneca’s Enhertu Wins EU Approval in Early Breast Cancer AstraZeneca’s Enhertu Wins EU Approval in Early Breast Cancer Read Post »
Health TidingsMerck’s Keytruda Outperforms Chemotherapy on PFS in dMMR Cancer Merck’s Keytruda Outperforms Chemotherapy on PFS in dMMR Cancer Read Post »
Health TidingsMerck’s Sac-TMT Cuts Death Risk by 32% in Endometrial Cancer Merck’s Sac-TMT Cuts Death Risk by 32% in Endometrial Cancer Read Post »
Clinical TrialsIambic’s IAM1363 Shows Early Activity Against Brain Metastases Iambic’s IAM1363 Shows Early Activity Against Brain Metastases Read Post »
New Drug ApprovalFDA Approves Pfizer’s TALZENNA Plus XTANDI for HRR-Mutated mHSPC FDA Approves Pfizer’s TALZENNA Plus XTANDI for HRR-Mutated mHSPC Read Post »
Clinical TrialsIncyte Reports Strong Responses with KRAS G12D and TGFβR2×PD-1 Therapies Incyte Reports Strong Responses with KRAS G12D and TGFβR2×PD-1 Therapies Read Post »
Clinical TrialsMirum Reports Positive Zilurgisertib Results in Children With FOP Mirum Reports Positive Zilurgisertib Results in Children With FOP Read Post »
Health TidingsLilly Reports Promising Results for Olomorasib in Lung Cancer Lilly Reports Promising Results for Olomorasib in Lung Cancer Read Post »
Health TidingsLongeveron Reports Fewer Cardiac Events in Infants With HLHS Longeveron Reports Fewer Cardiac Events in Infants With HLHS Read Post »
Health TidingsEledon’s Tegoprubart Outperforms Tacrolimus on Quality of Life After Kidn... Eledon’s Tegoprubart Outperforms Tacrolimus on Quality of Life After Kidn... Read Post »
Clinical TrialsCorcept Reports Positive BELLA Results for Lifyorli Triplet Corcept Reports Positive BELLA Results for Lifyorli Triplet Read Post »
Health Tidings Mergers & AcquisitionsIncyte, Genmab Partner on KRAS G12D Colorectal Cancer Trial Incyte, Genmab Partner on KRAS G12D Colorectal Cancer Trial Read Post »
Clinical TrialsJ&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADT J&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADT Read Post »
Clinical TrialsAgenus Reports 72% Complete Response with BOT+BAL in dMMR Colon Cancer Agenus Reports 72% Complete Response with BOT+BAL in dMMR Colon Cancer Read Post »
Health TidingsBayer’s Darolutamide Improves Four-Year Metastasis-Free Survival to 95% Bayer’s Darolutamide Improves Four-Year Metastasis-Free Survival to 95% Read Post »
Clinical TrialsAstraZeneca’s Sonesitatug Vedotin Meets OS but Misses PFS Endpoint AstraZeneca’s Sonesitatug Vedotin Meets OS but Misses PFS Endpoint Read Post »
Clinical TrialsJ&J Reports Strong Tumour Responses With RYBREVANT FASPRO J&J Reports Strong Tumour Responses With RYBREVANT FASPRO Read Post »
Health TidingsSystImmune Reports Higher Response Rates With Izalontamab Brengitecan in NS... SystImmune Reports Higher Response Rates With Izalontamab Brengitecan in NS... Read Post »
Health TidingsGenmab Reports Strong Disease Control With Petosemtamab in mCRC Genmab Reports Strong Disease Control With Petosemtamab in mCRC Read Post »
Health TidingsPfizer’s 25-Valent Pneumococcal Vaccine Shows Promising Phase 2 Resul... Pfizer’s 25-Valent Pneumococcal Vaccine Shows Promising Phase 2 Resul... Read Post »
Clinical TrialsParabilis Reports 100% Disease Control With Zolucatetide in Desmoid Tumors Parabilis Reports 100% Disease Control With Zolucatetide in Desmoid Tumors Read Post »
Clinical TrialsCatalYm Reports Higher Responses With Visugromab in Bladder Cancer CatalYm Reports Higher Responses With Visugromab in Bladder Cancer Read Post »
Clinical TrialsRoche’s Divarasib Improves Survival in KRAS G12C Lung Cancer Roche’s Divarasib Improves Survival in KRAS G12C Lung Cancer Read Post »
Clinical TrialsGSK’s Mo-Rez Shows 62% Response Rate in Ovarian Cancer GSK’s Mo-Rez Shows 62% Response Rate in Ovarian Cancer Read Post »
Health TidingsVertex’s Povetacicept Lowers Proteinuria, FDA Decision Nears Vertex’s Povetacicept Lowers Proteinuria, FDA Decision Nears Read Post »
Health TidingsRoche Reports Positive Phase 3 Results for Sefaxersen in IgAN Roche Reports Positive Phase 3 Results for Sefaxersen in IgAN Read Post »
Health TidingsIdorsia’s Daridorexant Shows Sleep Benefits in Children With Insomnia Idorsia’s Daridorexant Shows Sleep Benefits in Children With Insomnia Read Post »
Clinical TrialsGenmab’s Rina-S Reduces Death Risk by 57% in Ovarian Cancer Trial Genmab’s Rina-S Reduces Death Risk by 57% in Ovarian Cancer Trial Read Post »
Clinical TrialsPalleon Reports Faster Responses With HLX79/E-602 in pMN Trial Palleon Reports Faster Responses With HLX79/E-602 in pMN Trial Read Post »
Clinical TrialsRemibrutinib Cuts MS Relapses by Up to 35% in Phase 3 Trials Remibrutinib Cuts MS Relapses by Up to 35% in Phase 3 Trials Read Post »
Health TidingsTango’s Vopimetostat Regimen Shows 82% Response Rate PDAC Tango’s Vopimetostat Regimen Shows 82% Response Rate PDAC Read Post »
Health TidingsZai Lab’s Zoci Shows Strong Early Results in First-Line SCLC Zai Lab’s Zoci Shows Strong Early Results in First-Line SCLC Read Post »
Clinical TrialsTakeda’s Arcotatug Tavatecan Deliver Dual Survival Benefits in G-HOPE-001... Takeda’s Arcotatug Tavatecan Deliver Dual Survival Benefits in G-HOPE-001... Read Post »
Clinical TrialsBMS’s Zola-cel Shows Early Promise in Relapsing and Progressive MS BMS’s Zola-cel Shows Early Promise in Relapsing and Progressive MS Read Post »
Clinical TrialsRevMed Reports RASONQUE Survival Benefit Across RAS Subgroups RevMed Reports RASONQUE Survival Benefit Across RAS Subgroups Read Post »
Health Tidings Mergers & AcquisitionsZymeworks Grants Roche Global Rights to ZW209 in $813M Deal Zymeworks Grants Roche Global Rights to ZW209 in $813M Deal Read Post »
Health TidingsAdvanCell’s ADVC001 Shows Sustained Activity in Prostate Cancer AdvanCell’s ADVC001 Shows Sustained Activity in Prostate Cancer Read Post »
Clinical TrialsORIC Plans Phase 3 After Positive Enozertinib Results in NSCLC ORIC Plans Phase 3 After Positive Enozertinib Results in NSCLC Read Post »
Health Tidings Regulatory & Health PolicyEMA and AMA Recommend Faster Route to Bundibugyo Vaccine Trials EMA and AMA Recommend Faster Route to Bundibugyo Vaccine Trials Read Post »
Clinical TrialsAlnylam’s Brezosiran Delivers Up to 64% Mean Huntingtin Reduction Alnylam’s Brezosiran Delivers Up to 64% Mean Huntingtin Reduction Read Post »
Clinical TrialsEvaxion Reports Sustained EVX-01 Responses in Advanced Melanoma Evaxion Reports Sustained EVX-01 Responses in Advanced Melanoma Read Post »
Health TidingsGilead to Pay $1.275B for Oral IL-23R Inhibitor HCXT-2001 Gilead to Pay $1.275B for Oral IL-23R Inhibitor HCXT-2001 Read Post »
Health TidingsMerck, Moderna Show Improved Recurrence-Free Survival in Melanoma Trial Merck, Moderna Show Improved Recurrence-Free Survival in Melanoma Trial Read Post »
Clinical TrialsMineralys Reports 52.2% Albuminuria Reduction With Lorundrostat Mineralys Reports 52.2% Albuminuria Reduction With Lorundrostat Read Post »
Clinical TrialsVor Bio Reports Positive Two-Year TELIGAN Results in IgA Nephropathy Vor Bio Reports Positive Two-Year TELIGAN Results in IgA Nephropathy Read Post »
Clinical TrialsAbbVie Reports Phase 3 Success for Lutikizumab in Hidradenitis Suppurativa AbbVie Reports Phase 3 Success for Lutikizumab in Hidradenitis Suppurativa Read Post »
